Eloralintide with tirzepatide reduces weight in phase 2b trial

Aquesta entrada es mostra en anglès fins que se n'actualitzi la traducció.

Eli Lilly reported phase 2b results for investigational eloralintide with tirzepatide in 367 adults with overweight or obesity and type 2 diabetes. At 48 weeks, the combination group with the largest mean weight reduction lost 23.3%, compared with 14.8% for tirzepatide alone and 3.0% for placebo, using an analysis that assumes participants remained on treatment. Adverse events led to treatment discontinuation in 10.8% to 27.0% of combination recipients, versus 2.9% with tirzepatide alone and 16.7% with placebo; stomach and intestinal events were most common. These company-reported conference results concern an investigational combination, with phase 3 studies still planned at the time of the announcement.